New combo attack on liver metastases from nasopharyngeal cancer enters human trials

NCT ID NCT06788002

Recruiting now Disease control Sponsor: Hunan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether adding low-dose radiation to standard chemoimmunotherapy can better control liver tumors in people with nasopharyngeal carcinoma that has spread to the liver. The study will enroll 26 adults aged 18 to 70. Participants will receive low-dose radiation to the liver for 5 days, followed by chemotherapy (gemcitabine and cisplatin) plus an immunotherapy drug (penpulimab). The main goal is to see how long liver tumors stay under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: low-dose radiation, gemcitabine, cisplatin, penpulimab
What this could lead to: If successful, this could offer a more effective first-line treatment for nasopharyngeal cancer that has spread to the liver, potentially improving control of liver tumors and overall survival.
What could go wrong: This is a small, early-phase trial with only 26 participants, so results may not apply to everyone. Adding radiation to chemoimmunotherapy could increase side effects, and the treatment may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CANCINOMA (NPC)

Contacts and locations

Locations

Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410013, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410013, China
Hunan University of Medicine General Hospital
RECRUITING

Huaihua, Hunan, China
The Central Hospital of Shaoyang
RECRUITING

Shaoyang, Hunan, 422000, China
The First People's Hospital of Chenzhou
RECRUITING

Chenzhou, Hunan, 424300, China
Third Xiangya Hospital, Central South University,
RECRUITING

Changsha, Hunan, 410000, China
Xiangya Hospital of Central South University
RECRUITING

Changsha, Hunan, 410000, China
Yueyang Central Hospital
RECRUITING

Yueyang, Hunan, 414020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.